NDL Ventures Regulatory Approval

NDL Ventures Board Meeting Date

NDL Ventures Ltd intimated BSE and NSE of a board meeting on 13 November 2026 to consider unaudited results for the quarter and half year ended September 2026. The trading window stays closed from 1 October 2026 until 48 hours after the results are declared.

NDL Ventures Acquisition

NDL Ventures received NCLT Mumbai's order approving the merger by absorption of Hinduja Leyland Finance into it. The certified copy is awaited, and the scheme is subject to the order's conditions.

NDL Ventures Board Meeting Date

NDL Ventures will hold a board meeting on 2 November 2026 to consider unaudited Q2 and half-year results. The trading window stays closed for designated persons until 48 hours after results are published.

NDL Ventures Other Announcement

The company submitted its quarterly shareholding pattern as per Regulation 31 for the period ended September 30, 2026.

NDL Ventures Annual General Meeting

NDL Ventures held its 41st Annual General Meeting on September 21, 2026, considering financial statements, dividends, and related party transactions.

NDL Ventures Results Correction

NDL Ventures replied to an NSE query on missing segment details in its Q1 FY27 financials. The segment was reported as 'Other Financial Services' in XBRL.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.